Skip to main content

Vermillion's Q3 Net Loss Shrinks on Sharp Cost Cuts

NEW YORK (GenomeWeb News) – Vermillion yesterday reported no revenue for its third quarter ended Sept. 30, yet the firm managed to cut its net loss by 27 percent.
The firm, which changed its name in August to Vermillion from Ciphergen Biosystems, had no revenue for the quarter after selling its proteomics tools business to Bio-Rad Laboratories a year ago. The company had revenues of $4.7 million in the third quarter of 2006.
Vermillion cut its net loss to $5.1 million from $7 million year over year, due primarily to a drop in its sales and marketing costs to $516,000 from $3.2 million.
The firm’s R&D expenses also dropped 24 percent to $2.2 million from $2.9 million.
In addition to changing its name during the quarter, Vermillion also raised $20.6 million in a private placement. It intends to use the funds to support clinical studies on a variety of diagnostic tests it is developing.
Vermillion finished the quarter with $19.5 million in cash and cash equivalents.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.